Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

Recent developments in the oral GLP-1 market feature the Wegovy pill from Novo Nordisk and the Foundayo (orforglipron) pill from Eli Lilly, with both medications gaining significant approvals and market traction in 2025–2026.

The Wegovy pill received FDA approval in December 2025 as the first oral GLP-1 for weight management in the U.S., showing average weight loss of about 13.6%–16.6% in clinical trials, and has since surpassed 3 million prescriptions in less than six months, marking one of the strongest launches in pharma history.

Europe granted marketing authorization for the Wegovy pill in July 2026, making it the first GLP-1 tablet approved for obesity and overweight in the EU, following earlier approvals in the U.S., UK, UAE, and Bahrain.

Eli Lilly's Foundayo (orforglipron) was approved by the FDA on April 1, 2026, as another once-daily oral GLP-1 pill for obesity and overweight, with trial data showing up to 12.4% average weight loss and flexible dosing without fasting requirements, presenting a competitive alternative to Novo Nordisk's product.

Patient-facing tools such as the Oral GLP-1 Tracker app and Foundayo-specific trackers (e.g., Shotlee) have emerged to help users log doses, track weight, side effects, and medication levels for both Wegovy and Foundayo, signaling growing consumer engagement and digital support around these oral therapies.